USA - NASDAQ:MNPR - US61023L2079 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to MNPR. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-13 | Barclays | Initiate | Overweight |
| 2025-10-06 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-10-02 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-25 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-25 | BTIG | Maintains | Buy -> Buy |
| 2025-09-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-09-23 | Lake Street | Initiate | Buy |
| 2025-09-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-09 | BTIG | Initiate | Buy |
| 2025-09-03 | Oppenheimer | Initiate | Outperform |
| 2025-09-03 | Raymond James | Initiate | Strong Buy |
| 2025-08-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-07 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-23 | Chardan Capital | Initiate | Buy |
| 2025-04-02 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-10 | Piper Sandler | Initiate | Overweight |
| 2024-11-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-11 | Rodman & Renshaw | Initiate | Buy |
| 2024-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-11 | JonesTrading | Upgrade | Hold -> Buy |
| 2023-06-01 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-03-29 | Maxim Group | Downgrade | Buy -> Hold |
| 2023-03-28 | EF Hutton | Maintains | Buy |
17 analysts have analysed MNPR and the average price target is 99.28 USD. This implies a price increase of 21.71% is expected in the next year compared to the current price of 81.57.
The consensus rating for MONOPAR THERAPEUTICS INC (MNPR) is 83.5294 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering MONOPAR THERAPEUTICS INC (MNPR) is 17.